PHGE - BiomX Inc.
NYSE
->
Healthcare
->
Biotechnology
Ness Ziona,
Israel
Type: Equity
PHGE price evolution
PHGE
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $37.07 | $37.74 | $44.76 | $62.1 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $42.53 | $48.31 | $58.1 | $66.64 |
| Long term investments | ||||
| Property, plant & equipment | $8.99 | $9.31 | $9.5 | $9.83 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $51.9 | $58.38 | $68.74 | $77.99 |
| Current liabilities | ||||
| Accounts payable | $1.78 | $1.66 | $1.4 | $2.79 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7.48 | $6.49 | $9.85 | $11.04 |
| Long term debt | $11.8 | $12.93 | $14.1 | $14.41 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $25.34 | $25.64 | $28.73 | $30.45 |
| Shareholders' equity | ||||
| Retained earnings | -$130.91 | -$124.14 | -$116.65 | -$108.48 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 29 Jul 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $62.1 | $37.24 | $72.41 | $0 |
| Short term investments | ||||
| Net receivables | $0.05 | |||
| Inventory | ||||
| Total current assets | $66.64 | $60.67 | $84.53 | $0 |
| Long term investments | ||||
| Property, plant & equipment | $9.83 | $2.23 | $1.88 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.7 | $7.59 | ||
| Total investments | ||||
| Total assets | $77.99 | $70.36 | $92.12 | $0.06 |
| Current liabilities | ||||
| Accounts payable | $2.79 | $6.3 | $5.85 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $11.04 | $7.16 | $6.22 | $0.04 |
| Long term debt | $14.41 | $0.5 | ||
| Total noncurrent liabilities | $5.73 | $1.44 | ||
| Total debt | ||||
| Total liabilities | $30.45 | $12.89 | $7.67 | $0.04 |
| Shareholders' equity | ||||
| Retained earnings | -$108.48 | -$72.26 | -$42.17 | -$0 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $7.32 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | |||
| Interest expense | -$0.15 | |||
| Net income | ||||
| Net income | -$7.48 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 29 Jul 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $30.26 | $22.21 | ||
| Operating income | -$30.26 | -$22.21 | -$12.49 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.14 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$30.09 | -$20.56 | -$12.72 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$3.58 | -$8.07 | -$10.02 | $16.17 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.29 | $0.06 | $0.04 | $37.28 |
| Effect of exchange rate | $0.14 | $0.08 | -$0.03 | |
| Change in cash and equivalents | -$25.07 | -$24.39 | -$17.34 | $25.85 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 30 Jul 2018 |
|---|---|---|---|---|
| Net income | -$30.09 | -$20.56 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$24.45 | -$17.58 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $16.17 | -$10.86 | $19.74 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $37.28 | $0.13 | $61.55 | $0 |
| Effect of exchange rate | -$0.03 | |||
| Change in cash and equivalents | $25.85 | -$35.17 | $63.72 | $0 |
News
Fundamentals
| Market cap | $11.57M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 29.98M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 1.24 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.69 |
| Quick ratio | N/A |